Good News | Azvudine Won the First Prize of Henan Provincial Technical Invention Award for Dual-Target Treatment of AIDS

Recently, the People's Government of Henan Province issued the "Decisions on Science and Technology Awards of Henan Province in 2024", and granted the first prize of Henan Provincial Technical Invention Award to the project "development and application of the Class 1 innovative drug for the dual-target treatment of AIDS" of Azvudine. The Science and Technology Awards of Henan Province were presented at the conference, with Lou Yangsheng, Party secretary of Henan province, bestowing the honors and the provincial Governor Wang Kai presiding over the event.

Azvudine, an innovator drug in China, is a Class 1.1 innovative drug with fully independent intellectual property rights and was awarded the Golden Medal of China Patent Award. As the world's first dual-target (reverse transcriptase and viral infectivity factor) nucleoside oral drug for the treatment of HIV infection, it has been listed as one of the National Science and Technology Major Projects (Major New Drug Innovation), and it was included in the Chinese guidelines for the diagnosis and treatment of HIV/AIDS China. Recently, it has been successfully renewed in the 2024 National Reimbursement Drug List.

Pyrimidine nucleoside HIV inhibitors are often used as the backbone of cocktail therapy. They are often used with one kind of purine nucleosides (such as TDF or TAF) and one kind of non-nucleoside HIV inhibitors or protease inhibitors as a complete cocktail therapy. This has made great success and turned AIDS into an ordinary chronic disease. Azvudine is a novel pyrimidine nucleoside HIV inhibitor independently developed by Genuine Biotech.

Compared to Emtricitabine and Lamivudine, etc., Azvudine has the following unique advantages:(1) The world’s first dual-target mechanism of action makes it more effective in blocking virus replication; (2) Low drug resistance: This makes it more effective in the treatment of AIDS, especially in the case of fighting viruses that have developed resistance to other drugs, showing its advantages; (3) Low dose: Due to the strong anti-HIV activity, the clinically practical dose of Azvudine is very low, only 3 mg per day, which is 1% of Lamivudine; (4) Drug combination: Azvudine can be administered in combination with antiviral drugs of different mechanisms and function as the backbone medication in various two-drug or three-drug antiretroviral regimens; (5) Fewer drug interactions: Low dose of Azvudine contributes to fewer drug interactions.

As early as 2022, the project "Development and Application of Azvudine for the Treatment of COVID-19" won the first prize of Henan Provincial Technical Invention Award. Winning the prize again further affirms Azvudine' s innovative, clinical, and social value. Looking to the future, Genuine Biotech will live up to expectations and remain committed to pursuing innovation-driven research, attracting global talents, advancing core technological breakthroughs, and expediting drug R&D, with the aim to rapidly evolve into a globally competitive biopharmaceutical leader!